Mass cytometry conducted on the same BMA cells showed that in the phenotypically characterized FPD-MM stem cells, based on high surface expression of CLL1 (CLEC12A), CD117, and CD123, but low expression of CD11b, CD244 and CD86, HHT treatment reduced the expression of CD34, c-Myc, EVI1, MCL1, Bfl1, p53, p-RB, PU.1, RUNX1 and CDK6 (Fig. 4D). The gene discussed is BCL2A1; the disease is Miyoshi myopathy.